Dr. Konecny on the Value of PARP Inhibitors in Ovarian Cancer

Dr. Konecny on Response to PARP Inhibitors in Ovarian CancerПодробнее

Dr. Konecny on Resistance to PARP Inhibitors in Ovarian CancerПодробнее

PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChatПодробнее

The Evolution of PARP Inhibitors in Ovarian CancerПодробнее

Challenges With PARP Inhibitors in Ovarian CancerПодробнее

Dr. Konner on PARP Inhibitors in Ovarian CancerПодробнее

Dr. Konecny Discusses the Role of PARP Inhibitors in Ovarian CancerПодробнее

Dr. Konecny on the Use of PARP Inhibitors in Patients With Ovarian CancerПодробнее

Dr. Konecny on the Indications for PARP Inhibitors in Recurrent Ovarian CancerПодробнее

Dr. Secord on the Role of PARP Inhibitors in Ovarian CancerПодробнее

Dr. Ledermann on Response to Rucaparib in Recurrent Ovarian CancerПодробнее

Ovarian Cancer: Comparisons Between PARP InhibitorsПодробнее

Dr. Backes on Quality of Life With PARP Inhibitors in Ovarian CancerПодробнее

Dr. Berek Discusses the Impact of PARP Inhibitors on Ovarian CancerПодробнее

Dr. Crane on the Impact of PARP Inhibitors in Ovarian CancerПодробнее

Assessing the role of PARP inhibitors and immunotherapy in ovarian cancerПодробнее

PARP Inhibitors in Recurrent Ovarian CancerПодробнее

The promising potential of PARP inhibitors in ovarian cancerПодробнее

Clinical Data with PARP Inhibitors in Ovarian CancerПодробнее